**SUMMARIZED CONTENTS**

**BOOK I**

Preface .................................................................................................................. 1

I. The State of the Art of Transplantation .............................................................. 21
   A. Cellular and Molecular Mechanisms ............................................................ 23
   B. Clinical Transplantation .............................................................................. 61
   C. Immunosuppression ..................................................................................... 121

II. Current Controversies in Transplantation ....................................................... 137

III. Progress in Transplantation ........................................................................... 177
   A. Immunobiology .......................................................................................... 179
      Regulation of Antigen Expression ............................................................... 181
      Immunogenic Potential of Graft Components and Various Cell Types ....... 239
      T Cell Repertoire: Receptors, Subsets, Cell Functions ............................. 265
      Induction of the Transplantation Response ................................................ 296
      Recirculation Patterns of White Cells; Generation and Structure of the Inflammatory Response .......................................................... 338
      Effector Mechanisms of Graft Rejection .................................................... 375
      Interactions Between Graft and Inflammatory Cells ................................. 375
      Isolation and Function of Inflammatory Leukocytes ................................... 386
      Mechanisms and Inhibition of Target Damage ............................................. 412
      Tolerance and Enhancement ...................................................................... 446
      Induction of Transplantation Tolerance ....................................................... 446
      Mechanisms of Transplantation Tolerance .................................................. 483
      Isolation and Function of Suppressor Cells ................................................ 528
      Materno-Fetal Interactions ......................................................................... 554
      Biological Immunosuppression (Experimental) .............................................. 568
         Immune Sera ............................................................................................ 568
         Monoclonal Antibodies ........................................................................... 579
         Other Methods ........................................................................................ 624
      Summation of Immunobiology Poster Discussions ..................................... 635
   B. Immunogenetics and Histocompatibility ....................................................... 639
      HLA Matching and Transplant Survival ....................................................... 641
      Highly Sensitized Recipients ...................................................................... 716
      Immune Reactivity and Transfusions ........................................................... 735
      Relevance of Crossmatch Findings and Methodology ................................. 764
         Sensitized Patients .................................................................................. 764
         Antibody Specificity in Sensitized Patients .............................................. 773
         Methods of Crossmatch ......................................................................... 789
      Molecular Genetics of the Main Histocompatibility Complex .................... 811
      Immunogenetics and Polymorphism of the Main Histocompatibility Complex .......................................................... 839
      Posttransplant Immune Reactivity ............................................................... 890
      Summation of Immunogenetics and Histocompatibility Poster Discussions .......................................................... 902

**BOOK II**

III. Progress in Transplantation (continued)

   C. Experimental Transplantation .................................................................... 905
      Experimental Transplantation of Islets and Endocrine Tissue ..................... 907
         Pancreatic Islet Isolation .......................................................................... 907
         Sites of Pancreatic Islet Transplantation ................................................... 925
         Storage and Reduction of Immunogenicity ............................................... 933
         Immunosuppression ................................................................................. 946
      Results of Pancreatic Islet Transplantation ............................................... 957
      Xenografts and Artificial Pancreas ............................................................... 981
      Transplantation of Hepatocytes .................................................................. 989
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experimental Pancreas Transplantation</td>
<td>1004</td>
</tr>
<tr>
<td>Technical Aspects and Sites of Transplantation</td>
<td>1004</td>
</tr>
<tr>
<td>Diagnosis and Treatment of Rejection</td>
<td>1023</td>
</tr>
<tr>
<td>Experimental Heart and Heart/Lung Transplantation</td>
<td>1034</td>
</tr>
<tr>
<td>Heart</td>
<td>1034</td>
</tr>
<tr>
<td>Heart/Lung; Lung</td>
<td>1043</td>
</tr>
<tr>
<td>Diagnosis and Treatment of Rejection</td>
<td>1053</td>
</tr>
<tr>
<td>Experimental Liver Transplantation</td>
<td>1072</td>
</tr>
<tr>
<td>Experimental Transplantation of Kidneys, Composite Tissues, and Other Organ</td>
<td>1106</td>
</tr>
<tr>
<td>Kidney</td>
<td>1106</td>
</tr>
<tr>
<td>Composite Grafts, Intestine, and Neurological Tissue</td>
<td>1115</td>
</tr>
<tr>
<td>Experimental Xenografts</td>
<td>1137</td>
</tr>
<tr>
<td>Mechanism of Action of Cyclosporine and Other Immunosuppressive Drugs</td>
<td>1171</td>
</tr>
<tr>
<td>Mechanism of Action of Cyclosporine</td>
<td>1171</td>
</tr>
<tr>
<td>Other Effects of Cyclosporine</td>
<td>1205</td>
</tr>
<tr>
<td>Experimental Use of Cyclosporine</td>
<td>1230</td>
</tr>
<tr>
<td>Distribution of Toxic Effects</td>
<td>1230</td>
</tr>
<tr>
<td>Analogues and Use in Combination With Other Drugs</td>
<td>1265</td>
</tr>
<tr>
<td>New Immunosuppressive Drugs</td>
<td>1284</td>
</tr>
<tr>
<td>Drugs Presumably Affecting Lymphocytes</td>
<td>1284</td>
</tr>
<tr>
<td>Drugs Presumably Affecting Macrophages and/or Arachinodic Acid Metabolism</td>
<td>1297</td>
</tr>
<tr>
<td>Preservation of Organs</td>
<td>1321</td>
</tr>
<tr>
<td>Liver</td>
<td>1321</td>
</tr>
<tr>
<td>Heart and Lung</td>
<td>1332</td>
</tr>
<tr>
<td>Pancreas and Islets</td>
<td>1337</td>
</tr>
<tr>
<td>Kidney</td>
<td>1348</td>
</tr>
<tr>
<td>Effects of Cyclosporine on Suboptimally Procured Kidneys</td>
<td>1382</td>
</tr>
<tr>
<td>Experimental Transfusions</td>
<td>1407</td>
</tr>
<tr>
<td>Blood Constituents</td>
<td>1407</td>
</tr>
<tr>
<td>Effects on Graft Survival</td>
<td>1420</td>
</tr>
<tr>
<td>Mechanisms of the Transfusion Effect</td>
<td>1429</td>
</tr>
<tr>
<td>Transfusion of the Organ Donor</td>
<td>1467</td>
</tr>
<tr>
<td>Effects on Tumor Growth</td>
<td>1473</td>
</tr>
<tr>
<td>Summation of Experimental Transplantation Poster Discussions</td>
<td>1479</td>
</tr>
<tr>
<td>D. Clinical Transplantation: Kidney</td>
<td>1483</td>
</tr>
<tr>
<td>Living Donors</td>
<td>1485</td>
</tr>
<tr>
<td>Related Donors</td>
<td>1485</td>
</tr>
<tr>
<td>Unrelated Donors</td>
<td>1509</td>
</tr>
<tr>
<td>Special Donor and Recipient Groups</td>
<td>1518</td>
</tr>
<tr>
<td>Children</td>
<td>1518</td>
</tr>
<tr>
<td>The Aged</td>
<td>1530</td>
</tr>
<tr>
<td>Systemic Disease</td>
<td>1535</td>
</tr>
<tr>
<td>Blacks</td>
<td>1546</td>
</tr>
<tr>
<td>Nondialyzed Recipients</td>
<td>1555</td>
</tr>
<tr>
<td>Immunological Monitoring, Graft Histology and Cytology, and Other Diagnostic Methods</td>
<td>1559</td>
</tr>
<tr>
<td>Immunological Monitoring</td>
<td>1559</td>
</tr>
<tr>
<td>Needle Biopsy</td>
<td>1618</td>
</tr>
<tr>
<td>Fine Needle Aspiration Biopsy</td>
<td>1641</td>
</tr>
<tr>
<td>Urinary Cytology</td>
<td>1662</td>
</tr>
<tr>
<td>Other Methods</td>
<td>1667</td>
</tr>
<tr>
<td>Pharmacokinetics and Side-Effects of Cyclosporine</td>
<td>1695</td>
</tr>
<tr>
<td>Pharmacokinetics of Cyclosporine</td>
<td>1695</td>
</tr>
<tr>
<td>Nephrotoxicity</td>
<td>1737</td>
</tr>
<tr>
<td>Diagnosis of Cyclosporine Nephrotoxicity</td>
<td>1769</td>
</tr>
<tr>
<td>Other Side-Effects</td>
<td>1801</td>
</tr>
</tbody>
</table>
III. Progress in Transplantation (continued)

D. Clinical Transplantation: Kidney (continued)

Immunosuppression............................................................................................................ 1833
  Cyclosporine ..................................................................................................................... 1833
  Antilymphocyte Globulins .............................................................................................. 1874
  Monoclonal Antibodies .................................................................................................... 1898
  Triple and Quadruple Drug Combinations ...................................................................... 1911
  Other Protocols .............................................................................................................. 1961

Conversion of Immunosuppressive Therapy ................................................................. 1998

Preservation of Organs and Acute Tubular Necrosis ...................................................... 2037
  Procurement and Preservation of Organs ...................................................................... 2037
  Prevention of Acute Tubular Necrosis .......................................................................... 2056
  Cyclosporine and Early Transplant Function .................................................................. 2074

Chronic Rejection and Long-Term Results .................................................................... 2111

Viral Infections ................................................................................................................. 2126
  Cytomegalovirus and Herpes .......................................................................................... 2126
  Hepatitis (HB, AG) .......................................................................................................... 2150
  Acquired Immune Deficiency (HTLV-LAV) and Epstein Barr Virus ......................... 2161
  Diagnosis and Prophylaxis .............................................................................................. 2181

Other Complications ......................................................................................................... 2194
  Urologic and Nephrologic ............................................................................................... 2194
  Other ............................................................................................................................... 2211

Living Related Donors and Specific Transfusion .......................................................... 2248

E. Clinical Transplantation: Other Organs.................................................................... 2283

Pancreas and Islet Cell Transplantation ......................................................................... 2285
  Techniques, Results, and Complications ...................................................................... 2285
  Monitoring and Diagnosis of Rejection ......................................................................... 2329
  Islet Cell Transplantation ............................................................................................... 2352

Liver Transplantation ....................................................................................................... 2373
  Selection of Patients and Results .................................................................................. 2373
  Operative Procedures ...................................................................................................... 2406
  Immunosuppression ........................................................................................................ 2431
  Transplantation in Children ........................................................................................... 2447
  Biopsy Findings ................................................................................................................ 2451

Heart and Lung Transplantation ..................................................................................... 2487
  Selection of Patients and Results ................................................................................... 2487
  Heterotopic Heart Transplantation .................................................................................. 2512
  Immunosuppression ........................................................................................................ 2514
  Monitoring ....................................................................................................................... 2527
  Biopsy Findings ................................................................................................................ 2560
  Summation of Clinical Heart Transplantation Poster Discussions ........................... 2574

Transplantation of Other Organs ..................................................................................... 2576
  Summation of Clinical Transplantation (Other Organs) Poster Discussions .............. 2591

F. Bone Marrow Transplantation .................................................................................... 2595

Clinical Bone Marrow Transplantation ........................................................................... 2597
  Acute and Chronic Graft-Versus-Host Disease ............................................................. 2655
  Experimental Bone Marrow Transplantation ............................................................... 2707
  Bone Marrow Manipulation ........................................................................................... 2735

IV. Transplantation Today and Tomorrow .................................................................... 2763

Author Index ...................................................................................................................... 2787

Subject Index ..................................................................................................................... 2807
CONTENTS

BOOK III

IMMUNOSUPPRESSION

Cyclosporine

Australian Multicentre Trial in Cadaver Renal Transplantation Comparison of Short- and Long-Term Cyclosporine A Therapy With Conventional Therapy

B.M. Hall, A.G.R. Sheil, D.J. Tiller, I. Hardie, J. Mahoney, G. Thatcher, T. Mathew, N. Thompson, and P. Miach 1833

Risk Factors for Cadaveric Donor Allograft Survival in Cyclosporine-Prednisone-Treated Recipients


Factors Influencing Kidney Graft Survival in the Cyclosporine Era: A Multivariate Analysis

J. Tiwari, P.I. Terasaki, and M.R. Mickey 1839

The Effect of Cyclosporine A in Cadaver Donor Retransplants: A Surprising Effect of the Sex of the Donor

J.M. Cecka, J. Cicciarelli, and P.I. Terasaki 1842

Cyclosporine Versus Azathioprine in High Risk Cadaver Kidney Transplant Recipients: A Prospective Randomized Study

D.J. Norman, P. Wetzsteon, J.M. Barry, and W.M. Bennett 1845

The Results of Renal Transplantation With Cyclosporine in Immunologically High-Risk Patients


Cyclosporine in Cadaveric Renal Transplantation: A Comparison of Two Immunosuppressive Protocols

M. Koyle, R. Glassock, J. Raifer, and H. Ward 1849

Does Cyclosporine Eliminate the Need for Preparatory Blood Transfusions?

D.W. Stevens, C.P. Jensen, and L.E. Stevens 1850

Two-Year Results of a Prospective Randomized Comparison of Cyclosporine/Low Dose Steroid Immunosuppression With Azathioprine and Steroids in Renal Transplantation

C.J. Miery, P.J. Nel, J.H.R. Becker, and J.P. Pretorius 1852

A Prospective Study on the Influence of Cyclosporine and Azathioprine on Renal Allograft Survival and Function


Two-Year Fate of 100 Kidney Transplants Treated With Low-Dose Cyclosporine Without Biopsy Guidelines


(Continued)
CONTENTS
(continued)

Low-Dose Cyclosporine or Azathioprine One Year After Renal Transplantation
*M.A. Forwell, J.A. Bradley, J.D. Briggs, M.W. Brown, B.J.R. Junor,
S.G. Macpherson, and M.A. Watson 1858

Quality of Life on Cyclosporine Versus Conventional Therapy..............R.G. Simmons
and L.K. Abress 1860

Renal Transplantation in Presensitized Patients Treated With Cyclosporine
*D. Albrechtsen, G. Lundgren, A. Bratlie, H. Brynger, I. Fehrmann, L. Frödin,
H. Gäbel, A. Lindholm, and A. Flatmark 1862

Primary Cadaveric Renal Transplantation Using Cyclosporine in Patients Over Fifty
Years of Age..............................D.M. Mandelbaum, M.L. Henry, B.G. Sommer,
and R.M. Ferguson 1863

A Randomized Study of Cyclosporine With and Without Prednisone in Renal
Allograft Recipients ..........A.S. Macdonald, P. Daloze, R. Dandavino, S. Jindal,
L. Bear, J.B. Dossetor, J. Klassen, C.R. Stiller, B. Lockwood,
C.E. Reeve, and the Canadian Transplant Group 1865

Cyclosporine-Steroids Versus Conventional Therapy in Cadaver Kidney
Transplantation: Analysis of a Randomized Trial at Two Years..........P. Gianello,
J.P. Squifflet, Y. Pirson, M. Stoffel, Th. Dereme, and G.P.J. Alexandre 1867

Cadaveric Renal Transplantation After Pulsatile Perfusion, Histocompatibility
Matching, and Conversion to Cyclosporine Therapy .....................M. Milgrom,
G.K. Kyriakides, V. Esquenazi, L. Olson, and J. Miller 1873

Antilymphocyte Globulins

Superior Renal Allograft Survival and Decreased Rejection With Early High-Dose
and Sequential Multi-Species Antilymphocyte Globulin Therapy ........F. Thomas,

Sequential Antilymphoblast Globulin and Cyclosporine For Renal Transplantation
* B.G. Sommer, M.L. Henry, and R.M. Ferguson 1879

Place of Antilymphocyte Globulins in the Immunosuppressive Regimen for Kidney
Transplantation ........J.L. Touraine, N. Lefrancois, J.M. Dubernard, J.L. Garnier,
J.P. Eyggonnet, N. Gibelin, H. Betuel, and J. Traeger 1881

Use of Cyclosporine and Minnesota Antilymphoblast Globulin in the Early
Postoperative Treatment of Primary Cadaveric Renal Transplant Recipients
W. Kupin, K.K. Venkat, H.K. Oh, S. Dienst, and N.W. Levin 1882

Treatment of Acute Rejection Crisis by Antilymphocyte Globulins: A Randomized
Prospective Study in Pediatric Kidney Transplantation.......M. Broyer, P. Niaudet,
M. Bijaoui, and M-F. Gagnadoux 1886

(Continued)
Use of Antithymocyte Globulin and Cyclosporine to Treat Steroid-Resistant Rejection Episodes in Renal Transplant Recipients ........A.I. Benvenisty, G.A. Tannenbaum, D.J. Cohen, G. Appel, and M.A. Hardy 1889

Antilymphoblast Globulin Treatment of Steroid-Resistant Rejection in Cyclosporine Immunosuppressed Renal Transplant Recipients .............V.A. Tellis, A.J. Matas, T.A. Quinn, D. Glicklich, R.J. Weiss, R.J. Soberman, and F.J. Veith 1892

Alternative Antirejection Treatment With Steroids or Antilymphoblast Globulin in Renal Transplant Patients Receiving Cyclosporine ..................... S.A. Veremis, M.S. Maddux, R. Pollak, S.S. Kline, and M.F. Mozes 1893

Antibody Formation Following Administration of Antilymphocyte Serum G. Niblack, K. Johnson, T. Williams, W. Green, R. Richie, and R. MacDonell 1896

**Monoclonal Antibodies**


**Triple and Quadruple Drug Combinations**

Triple Combination of Low-Dose Cyclosporine, Azathioprine, and Steroids in First Cadaver Donor Renal Allograft........ D. Fries, C. Hiesse, B. Charpentier, P. Rieu, N. Neyrat, M. Cantarovich, M. Ouziala, J. Bellamy, and G. Benoit 1911


(Continued)
CONTENTS
(continued)

Quadruple Therapy for Cadaver Renal Transplantation ................. M.H. Deierhoi, H.W. Sollinger, M. Kalayoglu, and F.O. Belzer 1917

Triple Drug Therapy: An Alternative Regimen in Renal Transplantation
M.L. Henry, B.G. Sommer, and R.M. Ferguson 1920

Triple and Quadruple Therapy After Renal Transplantation in Patients From Developing Countries ................. M. Slapak, T. Shell, N. Digard, D.C. Gosling, G. Qerchi della Rovera, R.C. Crockett, and K. Ahmed 1922

Immunosuppression With Cyclosporine, Azathioprine, and Prednisolone in Cadaver Renal Allograft Recipients ............. R.M. Jones, J.A. Murie, R. Allen, A. Jaskowski, and P.J. Morris 1926


Intermodal Immunosuppression for Cadaver Renal Transplantation: Results Using Antilymphocyte Globulin, Azathioprine, Cyclosporine, and Prednisone
P. Halloran, D. Ludwin, R. Bear, M. Aprile, B. McQuarrie, R. Poole, and N. White 1931

A Controlled Prospective Trial of Triple Therapy With Low-Dose Azathioprine, Cyclosporine, and Methylprednisolone in Renal Transplantation .......... A. De Vecchi, A. Tarantino, G. Montagnino, F. Egidi, A. Vegeuto, L. Berardinelli, and C. Ponticelli 1933

A Controlled Trial of Triple Therapy in Renal Transplantation ............ J.R. Salaman, P.J.A. Griffin, W.B. Ross, and J.D. Williams 1935

Reduction of Nephrotoxicity and Improvement of Immunosuppression by Combination of Cyclosporine A and Azathioprine ........... W.D. Schareck, U.T. Hopt, G.H. Müller, B. Greger, T. Risler, and H. Bockhorn 1937

Decreased Interleukin 2 Production and Increased LEU 2a-Positive Suppressor Cells in Renal Transplant Patients on Triple Therapy with Mizonbine, Cyclosporine A, and Prednisolone .......... M. Okubo, Y. Kaneko, M. Mizukoshi, K. Inoue, N. Sato, K. Kamata, X-M. Chen, H. Uchida, and T. Endo 1940

A Flexible Immunosuppression Protocol for Organ Transplantation Utilizing Cyclosporine, Azathioprine, and Prednisone ............ R.T. Schweizer, M. Rovelli, L. Roper, and S.A. Bartus 1944

Cox Regression Analysis of Outcome Risk Factors in 519 Renal Allograft Recipients


(Continued)
CONTENTS
(continued)

Management of Immunosuppressive Problems in Renal Allograft Recipients
M.I. Lorber, S.M. Flechner, C.T. Van Buren, K. Sorensen, R.H. Kerman,
and B.D. Kahan 1951

Immunosuppression With Low-Dose Cyclosporine Combined With Bredinin and
Prednisolone .................... K. Aso, H. Uchida, K. Sato, K. Yokota, T. Osakabe,
Y. Nakayama, M. Ohkubo, K. Kumano, T. Endo, K. Koshiba,
K. Watanabe, and N. Kashiwagi 1955

An Immunosuppressive Protocol Compatible With the United States Kidney
Transplant Diagnosis Related Grouping ......................... F.P. Stuart, J.K. Stuart,
J.R. Thistlethwaite, Jr, A.O. Gaber, and J. Mayes 1959

Other Protocols

Pretreatment of Human Renal Allografts With Monoclonal Antibodies to Induce
Long-Term Tolerance .................. D. Taube, K.I. Welsh, M. Bewick, F.E. Dische,
A. Palmer, V. Parsons, and S. Snowden 1961

Results of the South-Eastern Organ Procurement Foundation Strategy for
Transplanting Sensitized Patients........ R.R. Bollinger, W. Vaughn, F. Sanfilippo,
B. Lucas, W. Lefor, T. Peters, and W. Bias 1964

A Randomized Study of Buffy Coat Transfusions in Cadaveric Renal Transplantation
D.J. Norman, L. Fletcher, and J. Barry 1967

Has Cyclosporine Really Relegated Pretransplant Blood Transfusion to Therapeutic
Obsolescence?........ J.S. Melzer, R.M. Husing, N.J. Feduska, S.J. Tomlanovich,
F. Vincenti, W.J.C. Amend, M. Garovoy, and O. Salvatierra, Jr 1971

Wide Field Low-Dose Total Lymphoid Irradiation in Clinical Kidney Transplantation
J.A. Myburgh, A.M. Meyers, J.R. Botha, P.D. Thomson, J.A. Smit, S. Browde,
and R. Lakier 1974

Comparison of Three Immunosuppressive Regimens in High-Risk Patients:
Immunologic Aspects ...... E. Renna Molajoni, A. Bachetoni, P. Cinti, F. Sallustio,

Adverse Effects of Low-Dose Azathioprine on Australian Primary Graft Survival

MLR Suppression and MLR-Suppressor Activity Induced by Thoracic Duct Drainage
Prior to Transplantation ................. Y. Ono, S. Ohshima, T. Kinukawa,
O. Matsuura, and S. Hirabayashi 1985

Renal Allograft Survival in Highly Sensitized Patients Treated With Cyclosporine

(Continued)
CONTENTS
(continued)

Early Postoperative Monitoring of Natural Anti-A and Anti-B Isoantibodies in
ABO-Incompatible Living Donor Renal Allografts .......... R. Reding, J.P. Squifflet,

The Impact of Selected Risk Variables on the Outcome of Renal Transplantation

Effects of Pretransplant Splenectomy: Univariate and Multivariate Analyses

A Controlled Trial Comparing Sequential Antilymphocyte Sera and Cyclosporine
Therapy to Conventional Therapy in Renal Transplant Recipients

CONVERSION OF IMMUNOSUPPRESSIVE THERAPY

Prolonged Cyclosporine Therapy to Induce Solid Engraftment After Renal
Transplantation ............... W. Weimar, D.J. Versluis, G.J. Wenting, F.H.M. Derkx,
M.A.D.H. Schalekamp, and J. Jeekel 1998

Improvement of Renal Function After Conversion From Cyclosporine Only to
Prednisolone-Azathioprine Followed by Late-Onset Graft Failure in Renal
Transplant Patients ............. A.M. Tegzess, W.J. van Son, J.M. Beelen, W.J. Sluiter,
S. Meijer, and M.J.H. Slooff 2000

Conversion From Azathioprine and/or Prednisolone to Cyclosporine A in Renal
Allograft Recipients .............................................. H. Ebel and H. Lange 2005

Conversion From Cyclosporine to Azathioprine Improves Renal Function Without
Increased Risk of Graft Failure .......... M.S. Maddux, S.A. Veremis, R. Pollak,
and M.F. Mozes 2007

Safe Conversion from Cyclosporine .......... P.L. Adams, J.M. Burkart, R.W. Hamilton,
W.B. Lorentz, M.C. Browning, J.H. Meredith, and E.R. Heise 2010

The Fate of Living Related Donor Kidney Recipients After Conversion From
Cyclosporine to Azathioprine .......... T. Oka, Y. Omori, I. Aikawa, T. Yasumura,
I. Nakai, and S. Matsui 2012

Elective Conversion From Cyclosporine to Azathioprine: Long-Term Follow-Up
P.S. Veitch, J.D. Taylor, J. Feehally, J. Walls, and P.R.F. Bell 2017

Cyclosporine to Azathioprine Conversion in Cadaveric Renal Transplant
T.A. Gonwa, D.D. Nghiem, and R.J. Corry 2018

Withdrawal of Methylprednisolone at the Sixth Month in Renal Transplant Recipients
Treated With Cyclosporine ....... L. Cristinelli, G. Brunori, G. Setti, A. Manganoni,
A.M. Manganoni, F. Scolari, S. Sandrini, P. Scaini, S. Savoldi, C. Camerini,
and R. Maiorca 2021

(Continued)
CONTENTS (continued)

Corticosteroid Withdrawal With Substitution of Azathioprine in Cyclosporine-
Treated Primary Cadaveric Renal Transplant Recipients...................... W. Kupin,

Stopping Prednisone in Kidney Transplant Recipients Taking Cyclosporine: Safety

Effects of HLA Matching and Panel Reactive Antibodies in the Development of
Rejection After Conversion of Cyclosporine To Azathioprine............... S.M. Zemel,
S.Y. Shen, M.R. Weir, F.J. Dagher, and F.R. Bentley 2029

Conversion of Cyclosporine to Azathioprine in Renal Transplant Patients ....S.Y. Shen,
S.M. Zemel, M.R. Weir, F.J. Dagher, and F.R. Bentley 2032

PRESERVATION OF ORGANS AND
ACUTE TUBULAR NECROSIS

Procurement and Preservation of Organs

The Value of Hormonal Therapy in Improving Organ Viability in the Transplant
Donor ........................................... D. Novitzky, D.K.C. Cooper, and B. Reichart 2037

Preservation of the Cortical Renal Microcirculation: A Prerequisite for Immediate
Renal Allograft Function....... D. Anaise, H. Lehr, H. Atkins, Z. Oster, A. Arnold,
W.C. Waltzer, and F.T. Rapaport 2039

Usefulness of Radionuclide Scintiphotography to Evaluate Preserved Kidney Viability
W. Waltzer, and F.T. Rapaport 2043

A Controlled Comparison of Kidney Preservation by Two Methods: Machine
Perfusion and Cold Storage .......... J.E. Heill, D.M. Canafax, D.E.R. Sutherland,
R.L. Simmons, M. Dunning, and J.S. Najarian 2046

Preservation Effect on Oligo-anuria in the Cyclosporine Era: A Prospective Trial With
26 Paired Cadaveric Renal Allografts .......... R. Mendez, R.G. Mendez, N. Koussa,
S. Cats, T.P. Bogaard, and U. Khetan 2047

Limiting Factors in Successful Preservation of Cadaveric Kidneys With Ischemia
Times Exceeding 50 Hours .......... G.M. Abouna, M.S. Samhan, M.S.A. Kumar,
A.G. White, and O.S.G. Silva 2051

Prevention of Acute Tubular Necrosis

The Effect of Intraoperative Fluid Management of the Incidence of Acute Tubular
Necrosis ... I. Dawidson, P. Peters, A. Sagalowsky, D. Abshier, and L. Coorpender 2056

(Continued)
CONTENTS

(continued)

The Causes and Consequences of Failure of Cadaver Kidneys to Function: A Case-Control Study...............M. Aprile, P. Halloran, S. Zeldin, P. Brasher, and V. Farewell 2058


The Influence of Cold Ischemia on the Function of Cadaveric Renal Transplants in Cyclosporine A-Treated Patients.... Hm. van Goor, R.M.H. Wijnen, W. Geerlings, A.M. Tegzess, and M.J.H. Slooff 2061


Does the Donor Age Influence Graft Survival in Renal Transplantation? G. Sakellariou, M. Daniilidis, E. Alexopoulos, A. Karagiannis, and M. Papadimitriou 2071

Cyclosporine and Early Transplant Function

Improved Early Course After Cadaveric Renal Transplantation by Reducing the Cyclosporine Dose and Adding Azathioprine...........G. Lundgren, D. Albrechtsen, H. Brynger, A. Flatmark, L. Frodin, H. Gäbel, H. Persson, and C.G. Groth 2074

Successful Use of Cyclosporine in Renal Grafts With Prolonged Ischemic Times R.W.S. Chang, D. Saltissi, A. Al Khader, M. Abomelha, and M. Jawdat 2080


The Effect of Acute Tubular Necrosis on Cyclosporine-Treated Kidney Transplants O.N. Paramasivan, P.J.A. Griffin, W.B. Ross, and J.R. Salaman 2085


(Continued)

2088

The Long-Term Deleterious Effect of Delayed Graft Function in Cyclosporine-Treated Renal Allograft Recipients.............. L.L. Rocher, C. Landis, D.C. Dafoe, C. Keyserling, R.D. Swartz, and D.A. Campbell, Jr

2093

Significance of Delayed Function in Cyclosporine-Treated Cadaver Kidney Transplants............... P. Belitsky, A.S. MacDonald, J. Gajewski, J. Boudreau, H. Bitter-Suermann, and A. Cohen

2096


2100


2104

Impact of Immunosuppressive Regimen on Early Posttransplant Renal Function J.H. Hong, G.S. Lipkowitz, C.Y. Yen, S.M. Greenstein, T. Manis, and K.M.H. Butt

2106

CHRONIC REJECTION AND LONG-TERM RESULTS


2111

High Long-Term Graft Survival Rates in Kidney Transplantation With the Sequential Association of Antithymocyte Globulin and Cyclosporine A Monotherapy M. Hourmant, F. Buzelin, P. Dubigeon, and J.P. Soulillou

2113


2115

Long-Term Survivor of Kidney Transplantation, Mortality, Rehabilitation, and Immunologic Reactivities....................... H.M. Lee, N. Kenyon, G. Mendez-Picon, and M.P. Posner

2120

Prevention of Chronic Rejection by Cyclosporine and Prednisone............ A.N. Arnold, D. Anaise, F. Miller, W.C. Waltzer, and F.T. Rapaport

2122

Promethazine: Results of Triple-Drug Immunosuppression for Kidney Transplantation T. Orłowski, Z. Gaciong, and L. Paczek

2124

(Continued)
CONTENTS
(continued)

VIRAL INFECTIONS

Cytomegalovirus and Herpes


Interaction Between Cytomegalovirus and Staphylococcus Aureus Protein A in Immunoglobulin Secretion and DNA Synthesis .......... T. Paulin and O. Ringdén 2133

Proliferative Response Against Cytomegalovirus and Prognosis of Renal Transplant and IgA Nephropathy Patients............. T. Sakamaki, H. Kashiwabara, K. Omori, N. Nagata, T. Hachisu, S. Tateno, H. Shishido, and T. Yokoyama 2135


Hepatitis (HBs Ag)

Renal Transplantation in Hepatitis B Surface Antigen-Positive Patients..... A.G. White, M.S.A. Kumar, O. Strannegard, and G.M. Abouna 2150


(Continued)
Acquired Immune Deficiency (HTLV-LAV) and Epstein-Barr Virus


HTLV-III/LAV Infection in Kidney and Liver Transplantation D. Shaffer, R.H. Pearl, R.L. Jenkins, S.M. Hammer, W.J. Dzik, J.E. Groopman, P.N. Benotti, and A.P. Monaco 2176


Diagnosis and Prophylaxis

T Cell Subset Analysis Predicts Virus Infection but not Rejection in Cyclosporine A-Treated Renal Allograft Recipients H.J. Metselaar, J. Jeekel, Ph.H. Rothbarth, L.M.B. Vaessen, G.J. Wenting, and W. Weimar 2181


Monitoring of the Serum Neopterin/Creatinine Ratio in Renal Transplantation D. Hacini, C. Guerin, P. Berthoux, G. Ville, and F. Berthoux 2185


(Continued)
CONTENTS
(continued)

OTHER COMPLICATIONS

Urologic and Nephrologic


Hemodialysis or Continuous Ambulatory Peritoneal Dialysis Before Transplantation: Prospective Comparison of Clinical and Hemodynamic Outcome
A. Odor-Morales, G. Castorena, C. Jimeno, J.C. Peña, J. Bordes, C. de la Rosa, and F. Chávez-Péón 2197


The Incidence of Membranoproliferative Glomerulonephritis in Renal Allografts M.J. Moritz, J.F. Burke, B.E. Jarrell, and R.A. Carabasi 2206

Disappearance of Mesangial IgA Deposits From the Kidneys of Two Donors After Transplantation ....... X. Ceuvas, J. Lloveras, M. Mir, J. Aubia, and J. Masramon 2208


Other

Cancers Following Cyclosporine Therapy ................................................................. I. Penn 2211

Cancer Incidence in Renal Transplant Patients Treated With Azathioprine or Cyclosporine .................. A.G.R. Sheil, S. Flavel, A.P.S. Disney, T.H. Mathew, and B.M. Hall 2214

Human Antibody Response to Antilymphocytic Preparations in Renal Transplant Patients .................. C.F. Shield III, A.J. Fucello, P. Marlett, and G. Goldstein 2217


(Continued)
Prospective Study and Long-Term Follow-Up of Liver Damage in Renal Transplant Recipients
S. Takahara, H. Ibara, Y. Ichikawa, S. Nagano, T. Fukunishi, T. Sonoda, and Y. Shinji

Mechanism of Liver Cell Injury From Iron Overload in Renal Transplant Recipients
K.V. Rao and W.R. Anderson

Symptomatic Renal Osteodystrophy After Renal Transplantation: Treatment with 1-α-Hydroxycholecalciferol
P.S. Williams, A.N. Hillis, A.J. Carty, R.A. Sells, and J.M. Bone

Type II Hyperlipoproteinemia, Hyperapobetalipoproteinemia, and Hyperalphalipoproteinemia Following Renal Transplantation: Prevalence and Precipitating Factors
R.P. Lowry, G. Soltys, R. Mangel, P. Kwiterovitch, and A.D. Sniderman

Peptic Ulcer Disease Following Renal Transplantation
S.J. Knechtle, K. Kempf, and R.R. Bollinger

Adrenal Function as an Index of the Immunosuppressive Activity of Glucocorticoids (Prednisolone) in Renal Allograft Recipients
M. Kozaki, T. Hirano, and K. Oka

Testicular Histology in Patients Receiving Renal Transplantation

Transmission of Medulloblastoma From Cadaver Donor to Three Organ Transplant Recipients

Kaposi's Sarcoma After Renal Transplantation
M. Al-Suleiman, A. Haleen, and A. Al Khader

Chromosome Aberration in Kidney Transplant Recipients

LIVING RELATED DONORS AND SPECIFIC TRANSFUSION

Three Year Experience of Donor Specific Transfusion and Concomitant Cyclosporine A
A.N. Hillis, J. Duguid, C.M. Evans, J.M. Bone, and R.A. Sells

Optimization of Donor Specific Blood Transfusion in Kidney Transplantation

Donor Specific Transfusions: A Five Year Experience With Alternative Protocols
D.J. Norman, K. Henell, L. Fletcher, and J. Barry

Kinetics of Antidonor Mixed Lymphocyte Culture Responses in Donor Specific Transfusion Plus Azathioprine-Treated Patients
W.J. Burlingham, A. Grailer, E.M.F. Sparks-Mackey, P.M. Sondel, and H.W. Sollinger
CONTENTS
(continued)

Interleukin 2 Response Inhibition Following Donor Specific Transfusions Given With Azathioprine ................................. J.D. Tyler, C.B. Anderson, and G.A. Sicard 2258


Role of Donor Specific Blood Transfusions in Prolongation of Kidney Graft Survival .......................... T. Matsumoto, K. Sakagami, and K. Orita 2264

Evaluation of the Risk Factors Associated With Donor Specific Blood Transfusion ................................. S. Vaidya, B.G. Sommer, E.A. Pagel, M. Koegel, and R.M. Ferguson 2268

The Effects of Donor Specific Transfusion and Cyclosporine A On Graft Outcome ............................... M. Haberal, Z. Oner, N. Aybasti, G. Arslan, M. Turan, and N. Bilgin 2269


Randomized Clinical Trial of Cyclosporine or Donor Specific Transfusions in High Risk Living-Related Donor Transplantation ....................... J. Bordes-Aznar, A. Odor, A. Dib-Kuri, F. Gabilondo, J. Kasep, J.C. Peña, J. Herrera-Acosta, and F. Chávez-Péón 2276

Related Donor Kidney Transplantation Is the Best Form of Treatment for Uremia .............................. C.G. Groth, I. Fehrman, O. Ringdén, and G. Lundgren 2278


CLINICAL TRANSPLANTATION: OTHER ORGANS

PANCREAS AND ISLET CELL TRANSPLANTATION

Techniques, Results, and Complications


(Continued)
Glucose Control After Simultaneous Segmental Pancreas and Kidney Transplantation  
I.G.M. Brons, R.Y. Calne, K. Rolles, P.F. Williams, N.G. Fishwick, and D.B. Evans  
2288

Recurrent Diabetic Nephropathy in Renal Allografts Placed in Diabetic Patients and  
Protective Effect of Simultaneous Pancreatic Transplantation...........S-O. Bohman,  
H. Wilczek, G. Tydén, G. Jaremko, G. Lundgren, and C.G. Groth  
2290

Metabolic Control at Two Months to 4.5 Years After Pancreatic Transplantation  
With Special Reference to the Role of Cyclosporine..........G. Tydén, C. Brattström,  
2294

Quadruple Immunosuppressive Therapy in Whole Pancreas Transplantation  
H.W. Sollinger, M. Kalayoglu, R.M. Hoffman, M.H. Deierhoi, and F.O. Belzer  
2297

Use of Recipient Mesenteric Vessels for Revascularization of Segmental  
Grafts: Technical and Metabolic Considerations...D.E.R. Sutherland, F.C. Goetz,  
K.C. Moudry, G.M. Abouna, and J.S. Najarian  
2300

Critical Analysis of Mortality and Graft Loss Following Simultaneous  
Renal-Pancreatic Duodenal Transplantation .................R.J. Corry, D.D. Nghiem,  
B. Schanbacher, and T.A. Gonwa  
2305

Preservation of Human Pancreatic Allografts in Cold Storage for Six to 24 Hours  
G.M. Abouna, D.E.R. Sutherland, G. Florack, J. Heil, and J.S. Najarian  
2307

Evolution of Metabolic and Endocrine Function in Ten Neoprene-Injected Segmental  
Pancreas Allografts at Three to 54 Months After Transplantation, Versus  
Preliminary Results in Nine Whole Pancreas Allografts With Enteric Diversion  
D. Cantarovich, J. Traeger, E. La Rocca, L.D. Monti, N. Lefrancois,  
F. Cantarovich, H. Betuel, N. Blanc-Brunat, J.L. Faure, A. Gelet,  
J.M. Dubernard, G. Pozza, and J.L. Touraine  
2310

A New Variant for Whole Pancreas Grafting.................G. Kootstra, J.P. van Hooff,  
P.J.G. Jörning, K.M.L. Leunissen, C.J. van der Linden, E. Beukers,  
and W.A. Buurman  
2314

Complications of Pancreas Transplantation—Effect of Technique  
L.H. Toledo-Pereyra and V.K. Mittal  
2319

Incidence of Fistulas Following Human Pancreas Transplantation—Positive Influence  
of Reabsorption of Pancreatic Secretions by the Peritoneum ............W-D. Illner,  
Th. Gottwald, D. Abendroth, and W. Land  
2323

Are Late Diabetic Complications Reversible After Pancreas Transplantation? A New  
Method of Follow-up of Microcirculatory Changes......D. Abendroth, W-D. Illner,  
R. Landgraf, and W. Land  
2325

Effects of Successful Combined Pancreatic and Renal Transplantation on Advanced  
Diabetic Neuropathy: A One-Year Follow-up Study.........H. Wilczek, G. Solders,  
R. Gunnarsson, G. Tydén, and A. Persson  
2327

(Continued)
CONTENTS

(continued)

Monitoring and Diagnosis of Rejection

Role of Pancreas Graft Biopsies in the Diagnosis and Treatment of Rejection After Pancreas Transplantation ........ D.E.R. Sutherland, D. Casanova, and R.K. Sibley 2329

Studies of the Exocrine Secretion of Segmental Pancreatic Grafts With Special Reference to the Diagnosis of Rejection and to the Penetration of Drugs Into the Pancreatic Juice ............. C. Brattström, G. Tydén, A.S. Malmborg, G. Lundgren, L. Öst, and C.G. Groth 2332

Monitoring of the Pancreatic Allograft by Analysis of Exocrine Secretion ....E. Steiner, G. Klima, D. Niederwieser, A. Königsrainer, M. Herold, and R. Margreiter 2336


Diagnosis of Rejection in Simultaneous Renal/Pancreas (Urinary Bladder Drained) Transplantation ............. D.C. Dafoe, D.A. Campbell, Jr, L. Rocher, R. Schwartz, and J.G. Turcotte 2345

Rejection in Pancreas Transplantation.......................... M. Prieto, D.E.R. Sutherland, L. Fernandez-Cruz, J.B. Heil, and J.S. Najarian 2348

Metabolic Monitoring in Renal-Pancreatic Transplants With Urinary Pancreatic Exocrine Diversion .................. D.D. Nghiem, T.A. Gonwa, and R.J. Corry 2350

Islet Cell Transplantation

Results of Cultured Fetal Pancreatic Islet Transplantation in Juvenile Diabetic Patients.......................... Gy. Farkas, S. Karácsonyi, M. Szabo, and G. Kaiser 2352

Effect of Human Fetal Pancreas Transplantation on Secretion of C-Peptide and Glucose Tolerance in Type I Diabetics .............. R.P. Robertson, K.J. Lafferty, C.E. Haug, and R. Weil III 2354

Experience With Human Fetal Pancreatic Allografts Over a Three-Year Period B.E. Tuch, G. Sheil, A.B.P. Ng, and J.R. Turtle 2357


(Continued)
LIVER TRANSPLANTATION

Selection of Patients and Results


Criteria of Selection for Liver Transplantation...................... D. Samuel, J.P. Benhamou, H. Bismuth, J. Gugenheim, M. Ciardullo, and F. Saliba 2383

Immunoprophylaxis of Hepatitis B Virus (HBV) Reinfection in Recipients of Human Liver Allografts................................................................. W. Lauchart, R. Müller, and R. Pichlmayr 2387


Incidence and Outcome of Donor Arterial Anomalies in Liver Allografts M. Decurtins, P.J. Friend, and R.Y. Calne 2394

Orthotopic Liver Transplantation for Secondary Malignancies of the Liver F. Mühlbacher and F. Piza 2396


(Continued)
## Operative Procedures

**Hepatic Artery in Liver Transplantation**


**Vascular Problems in Liver Transplantation**

G. Blumhardt, B. Ringe, W. Lauchart, M. Burdelski, W.O. Bechstein, and R. Pichlmayr

**Roux-En-Y Hepatojejunostomy: A Safe Procedure for Biliary Anastomosis in Liver Transplantation**

H. Bismuth, D. Castaing, J. Gugenheim, O. Traynor, and M. Ciardullo

**Experience With Veno-Venous Bypass in Human Liver Transplantation**

B. Ringe, A. Bornscheuer, G. Blumhardt, W.O. Bechstein, K. Wonigeit, and R. Pichlmayr

**Hemodynamics During Liver Transplantation With Veno-Venous Bypass**


**Selective Bowel Decontamination to Prevent Gram-Negative Bacterial and Fungal Infection Following Orthotopic Liver Transplantation**


**Vasopressin Use in Human Liver Transplantation**

P.M. Daloze, R. Arnoux, J. Corman, C. Smeesters, G. St Louis, and M. Beaudouin

**Prognostic Perioperative Factors Predicting the Outcome of Liver Transplantation**


**Beneficial Effect of Topical Ice Cooling in Donor Hepatonephrectomy**

S.I. Cho, B.P. Zalneraitis, and J.W. Bradley

## Immunosuppression

**A Randomized Clinical Trial Comparing OKT3 and Steroids for Treatment of Hepatic Allograft Rejection**


(Continued)
Contents (continued)

Conversion From Standard Cyclosporine to Low-Dose Cyclosporine and Azathioprine Therapy as Treatment of Cyclosporine-Related Complications in Liver Transplant Patients ............... J.D. Perkins, S. Sterioff, R.H. Wiesner, K.P. Offord, J. Rakela, E.R. Dickson, and R.A.F. Krom 2434


Transplantation in Children

Results and Problems in Paediatric Liver Transplantation in the Cambridge/Kings College Hospital Series: 1968 to July 1986 ................. N.V. Jamieson, R.Y. Calne, K. Rolles, N.D. Barnes, and A.P. Mowat 2447


Biopsy Findings

Use of Triple Therapy and Percutaneous Needle Biopsy to Minimize Graft Failure Following Liver Transplantation ........... J.A. St Cyr, B. Elick, D. Freese, H. Sharp, W. Payne, J. Bloomer, P. Stock, D. Snover, J.S. Najarian, and N.L. Ascher 2451


Correlation of Amino Acid Metabolism and Liver Biopsies in Preoperative and Postoperative Patients Receiving Hepatic Transplants ............. G.H.A. Clowes, Jr, R.H. Pearl, S. Bosari, R.L. Jenkins, and U. Khettry 2462

(Continued)
CONTENTS
(continued)

Class I Major Histocompatibility Complex Antigens are Induced on Hepatocytes in Rejecting Human Liver Grafts ............... S.K.S. So, D.C. Snover, N.L. Ascher, and J.L. Platt 2464

Modified Patterns of Major Histocompatibility Complex-Antigen Expression in Human Liver Grafts During Rejection........ G. Steinhoff, K. Wonigeit, B. Ringe, W. Lauchart, J. Kemnitz, and R. Pichlmayr 2466


Immunohistologic Labeling of Infiltrating T Lymphocytes in Hepatic Allografts: A Rejection Indicator......... J.D. Perkins, R.H. Wiesner, P.M. Banks, N.F. LaRusso, and R.A.F. Krom 2474

Consequences of Hepatic Artery Pathology After Orthotopic Liver Transplantation E.J. Hesselink, M.J.H. Slooff, K.H. Schuur, Ch. Bijleveld, and Ch. Gips 2476

Modifications of Biliary and Vascular Basement Membrane Laminin in Serial Hepatic Biopsies After Hepatic Transplantation in Man ............. M. Reynès, V. Tricottet, J.C. Gugenheim, D.J. Hartmann, A.M. Szekely, and H. Bismuth 2478


HEART AND LUNG TRANSPLANTATION

Selection of Patients and Results

The Influence of HLA Matching in Cardiac Allograft Recipients Receiving Cyclosporine and Azathioprine....................... M. Yacoub, H. Festenstein, P. Doyle, M. Martin, D. McCloskey, J. Awad, A. Gamba, A. Khaghani, and J. Holmes 2487

Current Results With Triple Therapy for Heart Transplantation...... R.M. Bolman III, M.T. Olivari, J. Saffitz, R. Sibley, J. Spadaro, C. Cance, and B. Elick 2490

Cardiac Transplantation in the Sixth Decade of Life ........... S. Szentpetery, M. Thames, J. Hanrahan, J. Morris, and R.R. Lower 2492

(Continued)
# CONTENTS

(continued)

A Detailed Study of Cytomegalovirus Infections in the First 160 Heart and Heart/Lung Transplant Recipients at Papworth Hospital, Cambridge, England  
*T.G. Wreghitt, M. Hakim, J.J. Gray, S. Kucia, R. Cory-Pearce, J. Wallwork, and T.A.H. English*  
2495

Immediate Graft Failure Treated With Partial Cardiopulmonary Bypass and Emergency Cardiac Retransplantation  
*J.S. Morris, R.R. Lower, and S. Szentpetery*  
2497

Clinical Heart Transplantation  
*J.G. Losman*  
2500

Selected Characteristics of 444 Heart Donors  
*R.W. Evans, D.L. Manninen, and A.M. Maier*  
2501

The Effect of Blood Pretransfusion on Orthotopic Cardiac Transplantation  
*A. Keogh, D. Baron, and V. Chang*  
2503

Late Acute Rejection After Cardiac Transplantation: Incidence and Treatment  
*H. Warnecke, S. Schueler, and R. Hetzer*  
2504

Endocrine Response to Exercise in Cardiac Transplant Patients  
*S. Schüler, D. Thomas, M. Thebken, U. Frei, T. Wagner, H. Warnecke, and R. Hetzer*  
2506

Neurologic Complications After Heart Transplantation: The Influence of Immunosuppression  
*H. Warnecke, S. Schueler, J. Schliffka, and R. Hetzer*  
2510

## Heterotopic Heart Transplantation

Are There Indications for Heterotopic Heart Transplantation Today?  
*E. Becerra, D.K.C. Cooper, D. Novitzky, and B. Reichart*  
2512

## Immunosuppression

Individualized Immunosuppression in Heart Transplant Recipients  
2514

Determinants of Cyclosporine Nephrotoxicity Following Cardiac Transplantation  
*M. Martin, D. Packham, C. Kingswood, H. Cairns, A. Khaghani, D. Thompson, and M. Yacoub*  
2516

Prevention of Toxic Side Effects of Cyclosporine in Heart Transplantation  
*S. Schüler, H. Warnecke, and R. Hetzer*  
2518

Results of “Immonoconversion” From Cyclosporine to Azathioprine in Heart Transplant Recipients With Progressive Nephrotoxicity  
2522

(Continued)
CONTENTS
(continued)

Avoidance of Perioperative Renal Toxicity by a Modified Immunosuppression Protocol

Monitoring

Acute Rejection of the Heart-Lung Allograft and Methods of Its Detection

Predictors of Rejection of Cyclosporine-Treated Cardiac Allograft Recipients

Increase In Transferrin Receptors as a Marker for Rejection and Infection in Human Cardiac Transplantation ................. K. Hoshinaga, T. Mohanakumar, N.L. Wood, S. Szentpetery, and R.R. Lower 2534


Cytoimmunologic Monitoring for the Noninvasive Diagnosis of Cardiac Rejection

First Pass Radionuclide Scintigraphy for Long-Term Follow-up After Heart and Heart-Lung Transplantation .... B.M. Kemkes, H. Reichenspurner, G. Osterholzer, M. Anthuber, N. Schad, A. Maccio, E. Erdmann, and R. Rienmüller 2543

Appearance of Cells Bearing the Interleukin-2 Receptor in Peripheral Blood of Cardiac Transplant Patients and Their Correlation With Rejection Episodes
  M. Coles, M. Rose, and M. Yacoub 2546

Immunological Monitoring of Heart Allograft Recipients .............. O. Lungu, E. Reed, C. Smith, E. Rose, C. Marboe, M. Hardy, K. Reemtsma, J. Fenoglio, and N. Suciu-Foca 2548

The Role of Bronchoalveolar Lavage in Diagnosing Pulmonary Rejection After Heart-Lung Transplantation .......... H-J. Schäfers, A. Haverich, L. Dammenhayn, T. Takayama, Th. Wahlers, K. Worch, and J. Kemnitz 2551

Frequency Analysis of Surface Electrocardiogram and Two-Dimensional Echocardiography for Noninvasive Diagnosis of Rejection After Heart Transplantation .... H. Reichenspurner, B.M. Kemkes, R. Haberl, Ch. Angermann, M. Weber, G. Osterholzer, M. Anthuber, and G. Steinbeck 2552


(Continued)
CONTENTS  
(continued)


Biopsy Findings


Biopsy Assessment of Donor Hearts Prior to and During Transplantation  S. Darracott-Canković, R. Cory-Pearce, P.G.I. Stovin, T. Wallwork, D. Wheeldon, and T.A.H. English 2564

Sequential Studies of Major Histocompatibility Complex Antigen Expression (Common Class I and Class II Determinants, DR or DQ) in Cardiac Biopsies Following Human Cardiac Transplantation.....A. Suitters, M. Rose, A. Khaghani, and M. Yacoub 2566

Myocyte Injury in Acute Cardiac Transplant Rejection and in Lymphocytic Myocarditis Is Similar and Reversible ... N.B. Ratliff, J.L. Myles, J.T. McMahon, L. Golding, R. Hobbs, G. Rincon, R. Sterba, and R. Stewart 2568

Transvenous Lung Biopsy: A New Technique ...........M. Hakim, P. Stovin, T. English, and J. Wallwork 2573

SUMMATION OF CLINICAL HEART TRANSPLANTATION POSTER DISCUSSIONS..................................................By J.G. Losman 2574

TRANSPLANTATION OF OTHER ORGANS

The Importance of HLA-DR Matching in Corneal Transplant Recipients Treated With Cyclosporine A............. H.v. Keyserlingk, G. Offermann, M. Wiederhold, and F. Hoffmann 2576

Use of Locally Injected Anti-T Monoclonal Antibodies in the Treatment of Acute Corneal Graft Rejection............................... G. Ippoliti and A. Fronterre 2579

Autotransplantation of the Adrenal Gland Using Microvascular Anastomosis  M. Matsuda 2581

(Continued)
Clinical Small Intestinal Transplantation Using Cyclosporine A and Methylprednisolone. Z. Cohen, R. Silverman, G. Levy, R. Wassef, and B. Langer 2588

SUMMATION OF CLINICAL TRANSPLANTATION—OTHER ORGANS—POSTER DISCUSSIONS

By C.G. Groth, O. Klintmalm, J.G. Losman, and N.L. Ascher 2591

BONE MARROW TRANSPLANTATION

CLINICAL BONE MARROW TRANSPLANTATION

Current Status of Bone Marrow Transplantation for Severe Aplastic Anemia: A Preliminary Report From The International Bone Marrow Transplant Registry

E. Gluckman for the Advisory Committee of the International Bone Marrow Transplant Registry 2597

European Experience of Bone Marrow Transplantation for Leukemia. O. Ringdén, F. Zwaan, J. Hermans, A. Gratwohl for the Leukemia Working Part of the European Group for Bone Marrow Transplantation 2600

A Prospective Randomized Study of Acute Graft-v-Host Disease in 107 Patients With Leukemia: Methotrexate/Prednisone v Cyclosporine A/Prednisone


(Continued)
CONTENTS


Distinct Types of Donor and Recipient T Cell Clones Functionally Related to Host-v-Graft Reactivity and Autologous Remission After Bone Marrow Transplantation For Severe Aplastic Anemia .......... E.M. Schneider, G. Pawelec, M. Haen, G. Ehninger, P. Ostendorf, J. Kömpf, V. Schöllhorn, and P. Wernet 2620

Bone Marrow Transplantation for Acute Leukemia: A Preliminary Report From the International Bone Marrow Transplant Registry .... R. Champlin, for the Advisory Committee of the International Bone Marrow Transplant Registry 2626

Bone Marrow Transplantation in Leukemia Using Family Donors Other Than HLA-Identical Siblings: A Preliminary Report From the International Bone Marrow Transplant Registry ...... M.M. Bortin, for the Advisory Committee of the International Bone Marrow Transplant Registry 2629

Discrimination Value of Class III and Glyoxalase Alleles for Selection of Histocompatible Bone Marrow Donors ..................... A. Wölpl, S. F. Goldmann, Th. Eiermann, and R. Arnold 2632


Risk Factors for Interstitial Pneumonitis Following Allogeneic Bone Marrow Transplantation for Severe Aplastic Anemia: A Preliminary Report R.S. Weiner and K.A. Dicke for the Advisory Committee of the International Bone Marrow Transplant Registry 2639

Long-Term Follow-up of Patients Who Received Transplants for Aplastic Anemia or Leukemia ............... E. Gluckman, A. Devergie, J. Meletis, H. De Castro, P. Lehn, J.H. Bourrhis, H. Keable, M. Cavazzana, F. Varrin, D. Bombail, E. Vilmer, N. Lemercier, N. Alby, M. Boiron, and J. Dausset 2643

Increased HLA-DR Compatibility Between Patients With Acute Myeloid Leukemia and Their Parents: Implications for Bone Marrow Transplantation N.A. Carpentier and M. Jeannet 2644

Fibronectin Restores Defective In Vitro Proliferation of Lymphocytes From Patients After Marrow Grafting .................... H-G. Klingemann, M-S. Tsoi, and R. Storb 2646

(Continued)
CONTENTS
(continued)

Prediction of Leukemic Relapse Soon After Bone Marrow Transplantation
J.A. Tratkiewicz and J. Szer 2648

Urinary Neopterin in Bone Marrow Recipients......................... L. Volin, S-E. Jansson, U. Turpeinen, U-M. Pomoell, and T. Ruutu 2651

ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE

Acute Graft-Versus-Host Disease Following Bone Marrow Transplantation in Humans: Prognostic Factors ...... M.M. Bortin, for the Advisory Committee of the International Bone Marrow Transplant Registry 2655

Thalidomide Induction of Bone Marrow Transplantation Tolerance.....G.B. Vogelsang, A.D. Hess, G. Gordon, R. Brundrette, and G.W. Santos 2658

Acute Graft-Versus-Host Disease: Pathogenesis and Prevention With a Monoclonal Antibody In Vivo......................J. Ferrara, A. Marion, G. Murphy, and S. Burakoff 2662

A Class II Antigen-Specific T Cell Clone Can Suppress Graft-Versus-Host Reactivity in Murine Allogeneic Bone Marrow Chimeras...............C.C-Y. Shih and R.L. Truitt 2664


Detection of Anti-non-MHC-Directed T Cell Reactivity Following In Vivo Priming After HLA-Identical Marrow Transplantation and Following In Vitro Priming in Limiting Dilution Cultures ..................C. Irle, B. Chapuis, M. Jeannet, M. Kaestli, N. Montandon, and B. Speck 2674

Haploidentical Bone Marrow Transplantation Using Soybean Agglutinin-Processed, T-Depleted Marrow ...........K. Matthay, D.W. Wara, A.J. Ablin, and M.J. Cowan 2678


Cyclosporine-Induced Syngeneic Graft-Versus-Host Disease: Assessment of T Cell Differentiation ..............A.D. Hess, G.B. Vogelsang, J. Heyd, and W.E. Beschorner 2683


Characteristics and Functions of Inflammatory Cells Isolated From Acute Graft-Versus-Host Disease Target Organs After Bone Marrow Transplantation in the Rat......................... R. Renkonen, D. Leszczynski, A. Wangel, and P. Häyry 2689

(Continued)
CONTENTS

(continued)

Reduction of Acute Graft-Versus-Host Disease–Related Mortality and Cytotoxic Lymphocyte Induction After Pretreatment of the Recipient With Anti-Asialo GM1 Antibody in the Murine P-to-F, Model K. Varkila and M. Hurme 2690

Role of Suppressor Cells and Thymic Hormone Function in the Early and Late Phases of Murine Graft-Versus-Host Reactions Ph. Lang, S. Moritz, W. Savino, C. Rostoker, and M. Dardenne 2692

Survival and Immune Recovery in Dogs Following Fetal Liver Transplantation G. R. Cain, R. E. Champlin, and R. P. Gale 2695


T Cell Depletion of HLA and Haploldentical Marrow Reduces Graft-Versus-Host Disease But It May Impair a Graft-Versus-Leukemia Effect P. J. Henslee, J. S. Thompson, E. H. Romond, M. A. Doukas, M. Metcalfe, M. E. Marshall, and J. S. MacDonald 2701

EXPERIMENTAL BONE MARROW TRANSPLANTATION

Hyperfractionation of Total-Body Irradiation and Engraftment of Marrow From DLA-Haploidentical Littermates L. K. Lösslein, H. J. Kolb, S. Porzsolt, E. Schäffer, S. Scholz, M. Meissner, E. Holler, W. Wilmanns, and S. Thierfelder 2707


Immunogenetic Analysis of Fully Allogeneic Rat Bone Marrow Transplantation E. Marquarding, J. Klempnauer, B. Steiniger, G. Filler, K. Wonigeit, and R. Pichlmayr 2715


Selective Multiplication of Hematopoietic Stem Cells For Bone Marrow Transplantation in Mice and Rhesus Monkeys G. Wagemaker 2721

(Continued)
CONTENTS (continued)


Lysosomal Enzyme Replacement of Neural Tissue by Allogeneic Bone Marrow Transplantation Following Total Lymphoid Irradiation in Canine Fucosidosis  

BONE MARROW MANIPULATION

Ex Vivo Depletion of Human Bone Marrow T Lymphocytes by Soybean Lectin Fractionation Followed by Treatment with an Anti-pan-T Cell (CD5) Ricin A-Chain Immunotoxin ..................... S. Siena, S. Villa, G. Bonadonna, M. Bregni, and A.M. Gianni 2735


HLA-DP Matching in Allogeneic Bone Marrow Transplantation .............. G. Pawelec, G. Ehninger, H. Schmidt, A. Rehbein, I. Balko, and P. Wernet 2741

Lymphocyte Reconstitution in Children Receiving Soybean Agglutinin T-Depleted Bone Marrow Transplants ............. M.J. Cowan, T. McHugh, W. Smith, D. Wara, K. Matthyay, A. Ablin, C. Casavant, and D. Stites 2744


Transfer of B Memory Cells to a T-Dependent Antigen in Murine Bone Marrow Transplantation ............................ B. Tsuberi, S. Slavin, E. Kedar, and B. Leshem 2747

Specific Inhibition of Hybrid Resistance of B6D2F1 Mice Pretreated With Parent Strain B6 Cells: Role of a Nylon Adherent Cell Induced in the Spleen of the B6-Pretreated B6D2F1 Hybrid .......... K. Kosmatopoulos, S. Orbach-Arbovus, and G. Mathé 2750

A Murine Model for Pharmacological Marrow Purging ... E.A. Copelan, S.C. Johnson, M.R. Grever, and P.J. Tutschka 2754

Transplantation of T Cell-Depleted Bone Marrow in Histoincompatible Rabbits: Improved Engraftment and Long-Term Chimeras After the Addition or Irradiated Donor Buffy Coat Cells and Irradiated Autologous Cryopreserved Bone Marrow ...................... A. Gratwohl, H. Baldomero, C. Nissen, and B. Speck 2756


(Continued)
CONTENTS (continued)

PART IV
TRANSPLANTATION TODAY AND TOMORROW

Immunology and Immunogenetics Synopsis ........................................... M. Simonsen 2765
Summary: Immunosuppression ................................................................. C.B. Carpenter 2770
Critical Issues in Bone Marrow Transplantation .................................... R. Storb 2774
Clinical Organ Transplantation ............................................................... A.G.R. Sheil 2782
Author Index ............................................................................................. 2787
Subject Index ............................................................................................. 2807
Incidence of Fistulas Following Human Pancreas Transplantation—Positive Influence of Reabsorption of Pancreatic Secretions by the Peritoneum

W-D. Illner, Th. Gottwald, D. Abendroth, and W. Land

There is evidence suggesting that transplantation of the pancreas is the only approach to a curative treatment of type I diabetes. The results of this surgical method improved during the last years with the new agent cyclosporine (Cs) and better patient management. In 1982 the one-year-survival-rate of pancreas grafts was about 20% worldwide, whereas in 1984 it had risen to 38%. In spite of this improvement, pancreas transplantation is still less successful than transplantation of other organs. One major reason for this fact is the difficulty in optimal handling of exocrine secretion.

Since 1979 the Munich group has been using prolamine (Ethibloc, Ethicon) in a consecutive series of 56 patients. Despite occlusion of the duct, a high incidence of pancreatic fistulas occurred, implicating the risk of a secondary bacterial contamination.

By modifying our surgical technique to a strictly intraperitoneal placement of the pancreas graft, we wanted to know whether the resorption capacity of the peritoneum would provide a reduction of the incidence of fistulas.

Patients and Methods

Fifty-two of those 56 patients received a pancreas and a kidney graft simultaneously. In these 52 patients we evaluated fistula incidence, frequency of re-intervention, and graft loss rate secondary to an infected fistula. According to the different surgical techniques there are two groups: group 1 (n = 25), in which the segmental pancreas graft was placed partially extra-and intraperitoneally; and group 2 (n = 27), in which the pancreas graft was placed strictly intraperitoneally along the ascending colon. The peritoneal cavity was continuously irrigated with saline solution over the first postoperative days.

Results

The incidence of fistulas in group 1 was 52% compared to 44% in group 2. The rate of secondary bacterial contamination of a fistula with subsequent surgical reinterventions showed no significant difference between both groups (2 vs 2.5). In five patients in group 1 the rescue of an infected fistula failed, compared to two cases in group 2.

Discussion

Our working hypothesis claimed that reabsorption of residual exocrine secretion by the peritoneum would reduce the incidence of fistulas. This could not be confirmed, because neither the fistula incidence rate nor the reoperating rate were statistically different. Specific and specific defense mechanisms of the peritoneum seem to have a positive effect against secondary infection of a fistula. Graft loss due to a fistula occurred in only 8% of patients treated with the modified technique (group 2) compared to 20% of the patients in group 1.

The improvement of graft survival rate (15% difference between group 1 and group 2) is probably based on defense mechanisms of the peritoneum. Therefore, we will continue to use the strictly intraperitoneal placement of duct-occluded pancreas grafts.

From the Transplantation Centre, Department of Surgery, Klinikum Grosshadern University of Munich.

Address reprint requests to Dr W-D. Illner, Transplantation Centre, Klinikum Grosshadern, Marchionistr.15, 8000 München 70, FRG.

© 1987 by Grune & Stratton, Inc.

0041-1345/87/1901-0877$03.00/0
REFERENCES